March 7 (Reuters) - I-Mab IMAB.O:
I-MAB ANNOUNCES ACCELERATED GIVASTOMIG PHASE 1B STUDY PROGRESS
I-MAB: PHASE 1B DOSE ESCALATION DATA EXPECTED TO BE PRESENTED IN 2H 2025
I-MAB: TOPLINE RESULTS FROM 40-PATIENT DOSE EXPANSION STUDY EXPECTED IN 1H 2026
Source text: ID:nGNX10fQFG
Further company coverage: IMAB.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.